Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled PEG-ADM in ARDS
NCT04417036Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Peptides, Polymer-based Nanoparticles
- Countries
- 7
01
Overview
A Phase 2 trial of adrenomedullin pegol in acute respiratory distress syndrome (ARDS), sponsored by Bayer. Started Jul 2020; status: terminated.
02
Drugs
adrenomedullin pegol
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04417036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417036.